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Bile duct ligation (BDL) is commonly employed as a model for hepatic periportal fibrosis. However,  
BDL is limited in that it is a severe procedure; is irreversible in practice; the severity of injury cannot be 
modulated and the procedure is associated with high mortality.  Methapyrilene (MP) administration has 
therefore been investigated as an alternative model.  Male rats were subjected to BDL or orally dosed 10 
with 150mg MP/kg body weight 3 times per week for up to 6 weeks.  Both procedures resulted in 
increases in serum alkaline phosphatase enzyme levels and periportal liver injury as judged by marked 
inflammatory cell recruitment to the periportal regions of the liver lobule.  Injury in both models was 
associated with an accumulation of pro-fibrogenic myofibroblast and fibroblast populations - and to 
fibrosis - in the periportal regions of the liver lobule.  Both procedures also caused an expansion in the 15 
number of biliary epithelial cells and a ductular reaction.  However, the studies with MP resulted in no rat 
mortality, in contrast to the BDL procedure.  Injury, inflammation, fibrosis and the ductular reaction that 
occurred in response to MP treatment all reversed within 3 weeks after MP treatment withdrawal. The MP 
model of periportal fibrosis is therefore a superior - more refined - model of periportal fibrosis than BDL 
since the degree of injury may be modulated (through alterations in injuring MP dose); the procedure is 20 
less severe; is subject to minimal mortality and is reversible (and therefore a more sensitive model to 
identify effective anti-fibrogenic drugs). 
Introduction 
Chronic liver damage caused by a variety of insults (e.g. 
infections such as hepatitis C; alcohol; obesity; genetic diseases 25 
such as Willson’s disease; autoimmune diseases such as primary 
biliary cirrhosis) results in hepatic fibrosis that limits the ability 
of the liver to regenerate, leading to cirrhosis, hepatocellular 
carcinoma and end-stage liver failure.1  There are currently no 
treatments for hepatic fibrosis, therefore fibrosis progression is 30 
responsible for a significant proportion of the morbidity and 
mortality associated with liver disease.2  Depending on the 
hepatic insult, the localisation and distribution of hepatic fibrosis 
may vary within the liver lobule. For example, alcoholic hepatitis 
produces centrilobular necrosis and fibrosis whereas viral 35 
hepatitis and cholestatic liver disease cause hepatic damage and 
fibrosis emerging from the portal tract (periportal region of the 
lobule).1 Accordingly, in the development of effective anti-
fibrogenic drugs for the liver, there is a need to test for 
therapeutuic efficacy using at least two experimental models of 40 
liver fibrosis – including at least a centrilobular as well as 
periportal model of fibrosis.1,3 
 
The most commonly used model for periportal fibrosis is bile 
duct ligation (BDL), a surgical procedure involving the double 45 
ligation of the common bile duct.4 The pathology resulting from 
BDL is similar to that seen in human chronic cholestatic disease:- 
initiation of a ductular reaction and activation of portal tract 
fibroblasts leading to portal-portal bridging fibrosis.4-6 However, 
BDL involves a surgical procedure that requires expertise.  50 
Surgery and the severity of the procedure often result in a 
significant level of mortality.4 This high level of mortality limits 
the long term use of BDL in animals (generally no longer than 4 
weeks ).7 Additionally, although the procedure can be reversed by 
additional surgery, this is unlikely to occur due to cost, time and 55 
welfare constraints.  The procedure in the United Kingdom is 
therefore classified as “severe” under the Animals (Scientific 
Procedures) Act 1986. 
 
Methapyrilene (MP) [N,N-dimethyl-N’-Pyridyl-N’(2-60 
thienylmethyl)-1,2-ethanediamine] is an H1 receptor antagonist 
that was used as a sedative and anti-histamine until its withdrawal 
in the late 1970s, when it was demonstrated to promote 
hepatocellular carcinoma in chronically-dosed rats.8 Subsequent 
work demonstrated that MP is a periportal hepatotoxin in rats.9-17  65 
MP is bio-activated in the liver by cytochromes P450, leading to 
the production of a reactive intermediate (potentially a thioether 
of MP S-oxide).14,18 The intermediate(s) is thought to disrupt 
mitochondria leading to hepatocyte apoptosis and necrosis and 
consequently hepatic inflammation.14,16,19 70 
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Based on the observation that MP causes periportal hepatic 
damage, we hypothesised that the chronic dosing of MP to rats 
would lead to a less severe, more controllable and reversible 
periportal fibrosis. We therefore compared the fibrosis generated 5 
by BDL and MP in rats.  The data in this paper demonstrate for 
the first time that MP produces a qualitatively similar fibrosis to 
BDL.  MP fibrosis therefore represents a more refined and 
superior model of hepatic periportal fibrosis than the BDL model. 
 10 
 
Results 
 
MP treatment caused a cholestatic injury and an increase in 
liver weight. 15 
 
To determine the effects of chronic MP dosing in rats, MP was 
administered by oral gavage at a dose of 150mg MP/kg body 
weight 3 times per week. This dose was chosen because it has 
previously been shown to cause moderate hepatic damage after 20 
acute administration.20  Table 1 shows that this dose of MP did 
not cause a loss of body weight, but similarly to BDL, caused a 
significant decrease in gain of weight compared to their 
respective controls.  Figure 1a indicates that MP treatment 
significantly increased serum ALP levels with non-significant 25 
increases in ALT and AST serum enzyme levels.  In contrast, 
BDL significantly increased serum ALP, ALT and AST levels 
compared to sham treated rats.  Serum γ-glutamyl transpeptidase 
(gGT) was undetectable in control animals (vehicle and sham 
controls) but was detectable in 3 of 5 MP treated rats and all rats 30 
subject to 14 days BDL (data not shown). Measurement of liver 
weight indicated that MP administration and BDL were also 
associated with a significant increase in liver weight as a 
proportion of total body weight (Figure 1b).   There was no 
mortality associated with the administration of MP, whereas BDL 35 
caused 30% mortality after 14 days. 
 
MP treatment caused portal tract inflammation and initiated 
an hepatic regenerative response. 
 40 
To determine whether liver injury caused by MP administration 
resulted in qualitatively similar pathological lesions, MP was 
administered to rats for 3 or 6 weeks, with an additional group 
allowed to recover after 3 weeks MP treatment to determine 
whether pathological changes were reversible.  45 
 
Liver sections from MP treated and control animals were stained 
with H&E and compared to liver sections from rats culled 14 
days after BDL surgery. Control animals showed occasional 
infiltrating leucocytes in the periportal region whereas both MP 50 
and BDL treated rats showed cell injury and necrosis in the 
periportal regions accompanied with marked significant increases 
in periportal inflammatory cells (Figure 2). MP treatment for 6 
weeks did not significantly increase inflammatory cell 
recruitment over that present at 3 weeks.  However, staining 55 
sections for neutrophils indicates that there was a progressive 
increased recruitment of neutrophils to the periportal regions of 
the liver lobule (Supplementary Figure 1). These adverse effects 
to MP were specific to the liver as judged macroscopically (data 
not shown).  Limited pathological examination of non-hepatic 60 
tissues including kidney (Figure 2), lung and spleen 
(Supplementary Figure 2) after 6 weeks of MP treatment support 
the suggestion that the liver is a target organ for MP toxicity. 
 
Expression of the marker for proliferating cells – PCNA21  – 65 
indicates that both BDL and MP administration resulted in an 
increase in PCNA positive hepatocytes and cholangiocytes, 
suggesting these cells undergo mitosis in response to injury 
(Figure 3, see also Supplementary Figure 3).  Figure 3 also shows 
that this proliferative response reversed in MP treated rats within 70 
3 weeks post withdrawal of MP. 
 
MP treatment caused an expansion of pro-fibrogenic cells and 
periportal fibrosis. 
 75 
Myofibroblasts and fibroblasts are recognised to play a 
fundamental role in deposition of extracellular matrix during 
hepatic fibrogenesis.22-24 Of these populations, portal tract 
fibroblasts have been implicated as the primary fibrogenic cell 
population involved in deposition of fibrotic extracellular matrix 80 
during the initial stages of periportal fibrosis.25   Portal tract 
fibroblasts have been shown to express vimentin.26  
 
Figure 4 demonstrates that a low number of cells positive for 
vimentin were present in liver sections from control animals and 85 
that these cells were evenly spread throughout the hepatic lobule. 
After MP treatment or BDL, the number of vimentin positive 
cells was significantly increased around periportal regions.  
Significantly more periportal vimentin staining was seen after 6 
weeks MP than after 3 weeks MP. The significant increase in the 90 
number of vimentin positive cells after 3 weeks MP treatment 
was reversed after a 3 week recovery period (Figure 4). 
 
Myofibroblasts are a pro-fibrogenic cell population associated 
with peri-sinusoidal and centrilobular injury,22,23,27 and express 95 
the marker α-SMA.28 Figure 5 demonstrates that only smooth 
muscle cells surrounding portal arterioles expressed  α-SMA in 
liver sections from control rats. In BDL and MP treated rats, there 
was a significant increase in the number of periportal α-SMA 
positive cells. Liver sections from rats treated with MP for 6 100 
weeks had significantly more periportal α-SMA positive cells 
than rats treated for 3 weeks. Similar to periportal vimentin 
staining, the significant increase in the number of periportal α-
SMA positive cells seen in rats after 3 weeks MP was reversible 
after 3 weeks vehicle treatment. 105 
 
Sirius red staining for collagen fibres showed that both BDL and 
MP treatment induced significant periportal fibrosis (Figure 6). 
Since biliary fibrosis severity can be somewhat heterogeneous 
throughout the liver, image analysis was performed (by an 110 
experimenter blinded to the identity of the treatments as outlined 
in the methods section) on 10 randomly selected portal tracts per 
section per rat to robustly test the effects of MP on fibrogenesis 
and recovery.  Sirius red staining quantification (Figure 6) and 
hepatic hydroxyproline contents (Supplementary Figure 4) 115 
confirm MP treatment for both 3 and 6 weeks caused a significant 
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increase in hepatic collagen content and therefore fibrosis.  
Prolonged treatment with MP (6 weeks) led to a significant 
increase in periportal fibrosis compared to that seen after 3 weeks 
and 14 days BDL (Figure 6). The increase in periportal fibrosis 
after 3 weeks was reversible as rats treated with 3 weeks MP 5 
followed by 3 weeks vehicle no longer showed significant 
periportal collagen deposition.   Central veins appeared similar 
between MP treated and control animals indicating that MP 
primarily caused periportal damage and fibrosis.  
 10 
MP treatment caused a ductular reaction. 
 
Ductular reaction is a regenerative response involving the 
significant expansion of CK-19 positive cholangiocytes and it is 
thought to play an important role in fibrogenesis.29 Figure 7 15 
shows that both BDL and MP gave rise to a ductular reaction 
with clear evidence of bile duct expansion. The reaction was 
significantly more severe after 6 weeks than 3 weeks of MP 
treatment, with a reverse in ductular reaction within 3 weeks after 
MP withdrawal (Figure 7). 20 
 
Chronic MP treatment caused a significant and reversible up-
regulation of expression of genes associated with fibrogenesis. 
 
The expression of genes associated with fibrogenesis was 25 
measured to place the changes observed in the liver after MP 
treatment in a more quantitative context to BDL.  Table 2 
demonstrates that both BDL and MP treatment up-regulated the 
expression of a variety of mRNAs associated with fibrogenesis - 
α-SMA, collagen 1A1 (COL1A1), MMP-2, TGF-β1, TGF-β2, 30 
TIMP-1 and vimentin.  The expression of these genes also 
returned to basal levels in the group of rats treated with MP for 3 
weeks followed by a 3 week recovery. 
 
 35 
Discussion 
 
A major complicating factor in chronic liver disease is fibrosis, 
for which there are no treatments indicated except 
transplantation. Fibrosis therefore remains a major determining 40 
factor in the high rate of mortality arising from chronic liver 
disease worldwide.1,2  Models of periportal fibrosis are important 
in research into anti-fibrogenics. This is because it is 
recommended that anti-fibrogenics are tested in both at least one 
centrilobular and periportal model of fibrosis (due to the different 45 
cell types contributing to fibrogenesis1,3,25).  In view of the 
limitations associated with the BDL model, chronic MP dosing 
was investigated as an alternative. 
 
Chronic MP administration of rats significantly elevated serum 50 
ALP levels suggesting that MP caused a cholestatic injury with 
evidence of a trend toward hepatocyte necrosis (Figure 1). BDL 
conversely significantly elevated all liver serum markers. The 
absence of significant ALT and AST serum activity after MP 
treatment is likely because the dose chosen caused less severe 55 
injury compared to BDL and hepatic regenerative pathways were 
sufficient to remove and replace damaged hepatocytes between 
MP doses. Importantly, MP treatment unlike BDL caused no 
mortality and there were no complications associated with the 
procedure. 60 
 
Qualitative similarities between the pathology of BDL- and MP-
induced fibrosis were seen at several levels. Inflammation is 
generally a pre-requisite for the development of fibrosis.1 
Analysis of liver histology by H&E staining (Figure 2) showed 65 
that MP and BDL caused significant increases in the number of 
inflammatory cells in and around the portal tracts, which has been 
seen previously after both MP and BDL treatment.9,10,30 PCNA 
immunostaining showed that 6 weeks MP treatment and BDL 
both significantly increased hepatocyte and cholangiocyte 70 
proliferation (Figure 3) demonstrating that both treatments led to 
hepatic damage and activation of hepatic regenerative pathways, 
although any role for the bi-potential progenitor (oval) cell, if 
any, in this process could not be determined from the studies as 
designed.  75 
 
In terms of fibrogenic cells, the numbers of myofibroblasts and 
portal tract fibroblasts in the periportal region positively 
correlated with the length of MP administration and their 
numbers significantly decreased following the cessation of MP 80 
treatment (Figures 4 and 5). Sirius red staining of liver sections 
from treated rats demonstrated that MP administration was 
associated with significant increased expression of COL1A1 and 
periportal deposition of collagen (Table 2 and Figure 6) in a 
manner that mirrored the changes in fibrogenic cell populations. 85 
Based on sirius red stained liver sections, the severity of fibrosis 
in BDL sits between the severities seen between 3 and 6 weeks of 
MP treatment.    
 
Spontaneous reversal of fibrosis is recognised to occur in some 90 
patients where the underlying cause of hepatic insult is 
successfully treated, however the processes that underlie this 
reversal are poorly understood.1 The severity of periportal 
fibrosis in MP treated rats correlated with the number of pro-
fibrogenic cells. The resolution of fibrosis seen in rats treated 95 
with MP for 3 weeks followed by vehicle for 3 weeks is therefore 
likely to be the result of apoptosis or reversal of the pro-
fibrogenic phenotype of these populations. This may result from a 
decline in inflammation and associated pro-fibrogenic growth 
factors released from inflammatory cells. Expression of hepatic 100 
TGF-β1 and TIMP-1 mRNAs to control levels in rats treated with 
MP for 3 weeks followed by vehicle for 3 weeks (Table 2), 
supports this hypothesis. The ease of reversal in this model 
facilitates its use as a method to study the reversal of periportal 
fibrosis, along with other rodent models of xenobiotic induced 105 
biliary fibrosis,31,32 as an alternative to BDL reversal.  
 
Ductular reaction promotes fibrosis development as ductules are 
pro-fibrogenic through the release of a range of chemokines, 
cytokines and growth factors that promote inflammation and 110 
fibrosis.29,33 The expansion of ductal cells was quantified by CK-
19 staining and showed that MP caused a ductular reaction 
similarly to BDL in rats (Figure 7). The ductular reaction induced 
by MP was also shown to be reversible.  Chronic MP treatment 
caused liver damage and activation of a ductular reaction in a 115 
more gradual manner relative to BDL. The use of a MP model for 
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the study of this phenomenon would therefore allow for a longer 
time frame for study of the early stages of a ductular reaction.  
 
It is clear from much of the data in this paper that BDL resulted 
in higher levels of many biomarkers of liver disease when 5 
compared to MP treatment at the dose employed. This is because 
BDL causes severe, constant and uncontrollable hepatic damage 
which likely is the cause for the high rate of mortality associated 
with the procedure. Dosing of MP is a more controllable model 
which also allows for some degree of hepatic regeneration to 10 
occur.  There is also the option of modifying the doses employed 
to increase the severity of injury.  The MP model may therefore 
be a superior model of human hepatic periportal fibrosis. This is 
primarily because in humans with chronic hepatic disease, 
fibrosis develops gradually and is frequently reversible when the 15 
underlying cause is removed.3  
 
In terms of potential drug interactions, the dosing of MP has been 
shown to cause a reduction in CYP2C11 and CYP3A activity in 
rats in vivo although the activity of the CYP1A and CYP2B 20 
families are unaffected by MP treatment.19  Knockout of the H1 
receptor has been shown to have no effect on hepatic injury in a 
murine model of liver injury34 - the antagonistic action of MP on 
the H1 receptor is therefore not predicted to have a significant 
effect on MP induced hepatic damage.  If the efficacy of anti-25 
fibrogenics is being tested in periportal fibrosis generated by MP, 
drug interactions should be considered in analysis of results.  MP 
is an H1 antagonist in the rat35 and mast cells increase in number 
in fibrotic tissue36 and contribute to the progression of fibrosis via 
the release of mediators such as histamine, tryptase, heparin and 30 
fibroblast growth factors.37  Furthermore, the proliferation of 
small cholangiocytes has been shown to be promoted by 
histamines.38  Most compounds used in fibrosis studies will have 
”off target” effects with respect to toxicity that may also 
modulate subsequent fibrogenic responses.  With drugs, there 35 
may be effects associated with known pharmacological targets 
(e.g. paracetamol and cyclooxygenase inhibition39).  However, 
even the commonly employed centrilobular hepatotoxin CCl4 
(which injures hepatocytes via a CYP2E1-mediated lipid 
peroxidation mechanism1) has been shown to inhibit protein 40 
kinase C activity by 50% in cells at a concentration of 1uM.40 
 
It has been shown here for the first time that chronic 
administration of MP leads to development of reversible hepatic 
periportal fibrosis with characteristics qualitatively similar to that 45 
seen after BDL in male rats, but without the requirement for 
surgery, distress and high mortality rates. Use of MP as an 
alternative to BDL would allow for modulation of fibrosis 
severity through changing the dosing regimen, whilst allowing 
fibrosis formation to be reversed if required. Chronic MP 50 
administration is therefore a refined alternative to BDL producing 
a reproducible model of reversible periportal fibrosis in rats. 
 
 
Materials and methods 55 
 
Animal studies 
Male Sprague-Dawley rats (230-250g body weight) were 
purchased from Charles River (Kent, UK) and housed in 
accordance with Home Office guidelines. Rats were kept no more 60 
than 5 per cage. Food and water for animals were available ad 
libitum and conditions were kept at 23°C ± 1°C on a 12 hour 
light/12 hour dark cycle at 47% humidity. Rats were dosed with 
150mg methapyrilene hydrochloride (Sigma, Poole, UK)/kg body 
weight from a 150mg/ml phosphate buffer saline (PBS, Sigma) 65 
stock by oral gavage 3 times per week. For the initial pilot study, 
rats were dosed with MP or control vehicle (1ml/kg body weight 
PBS) for 3 weeks. For the reversibility study, rats were dosed for 
3 weeks (with 3 weeks for recovery) or continuously for 6 weeks. 
Body weight was measured 3 times per week. After 0, 21 or 42 70 
days, the rats were killed by CO2 asphyxiation followed by 
cervical dislocation. Tissues and bloods were then removed for 
subsequent analysis. Bile duct ligation was carried out by double 
ligation of the common bile duct essentially as previously 
described on Sprague-Dawley rats.40,41 Sham operated rats 75 
underwent the same procedure, but the bile duct was not ligated. 
After surgery rats were kept in a warm room and closely 
monitored. BDL rats were killed and livers harvested at 14 days 
post surgery. Experiments were performed under a UK Home 
Office licence with Local  Ethics Committee approval. 80 
                   
Serum biochemistry  
Serum was prepared from blood samples by centrifugation and 
measured for serum (alanine aminotransferase (ALT), alkaline 
phosphatase (ALP) and aspirate aminotransferase (AST) 85 
essentially as previously described.42 
   
Histology and immunohistochemistry 
Organs were fixed in 10% buffered formalin and processed as 
previously described.42 Haematoxylin and eosin (H&E) and sirius 90 
red staining were carried out as previously described.42  
Neutrophils were identified using a naphthol AS-D chloroacetate 
esterase stain (Sigma Chemical Company, Poole, UK) following 
the recommended protocol. Immunohistochemistry for 
proliferating cell nuclear antibody (mouse anti-PCNA, Abcam, 95 
Cambridge, UK) α-smooth muscle actin (α-SMA, rabbit anti-α-
SMA, Abcam), cytokeratin-19 (CK-19, rabbit anti-CK-19, 
Abcam) and vimentin (rabbit anti-vimentin, Abcam) was 
performed as previously described.42   For all immunostaining, 
sodium citrate antigen retrieval was used to expose epitopes and 100 
primary antibodies were used at a 1:250 dilution. Di-amino 
benzidine (Dako, Ely, UK) was used to visualise secondary 
antibody binding to primary antibodies (anti-mouse/HRP or anti 
rabbit/HRP, 1:250 dilution, Dako). All sections were 
counterstained with haematoxylin prior to mounting. 105 
 
Inflammatory cell or neutrophil infiltration were calculated by 
counting the number of periportal leucocytes in and around 6 
random portal tracts per section from the H&E or esterase stained 
sections respectively.  PCNA immunostaining was quantified by 110 
counting the number of PCNA positive hepatocytes and 
cholangiocytes around 5 random portal tracts per section at x20 
magnification.  Sirius red, α-SMA, CK-19 and vimentin staining 
were quantified by densitometry analysis using Qwin software 
(Leica, Wetzlar, Germany) after manually specifying the 115 
threshold for positive staining. The threshold was selected to 
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ensure consistent measurement of staining across different 
sections. Analysis was carried out at x10 magnification, focusing 
on portal tracts in 10 random fields per section. All 
quantifications were carried out by a researcher blinded to the 
treatment groups.  For whole liver lobule sirius red quantification, 5 
slides were scanned using a Leica SCN400 slide scanner and then 
analysed for positive staining using the accompanying slidepath 
software. 
  
Quantitative real-time PCR 10 
 RNA was purified from liver samples using TRIzol (Life 
Technologies, Paisley, UK), DNAse-treated using RQ1 DNAse 
(Promega, Southampton, UK) and complementary DNA then 
synthesised using MML-V reverse transcriptase (Promega), 
following the manufacturer’s instructions. Quantitative real-time 15 
PCR was carried out using SYBR green (Sigma) on a 7500 Fast 
thermocycler (Applied biosciences, Paisley, UK) The sequences 
of the primers used were: rCOL1A1, US 5'- 
TGTGTTGCTGAAAGACTACCTCGT -3' DS 5'- 
AGTTGCCCCGGTGACACACAA -3'; rTGF-β1, US 5'- 20 
CGAGCCCGAGGCGGACTACT -3' DS 5'- 
ATAGATTGCGTTGTTGCGGTCCACC -3'; rTGF-β2, US 5’- 
TTCAGAATCGTCCGCTTCGAT -3’ DS 5’- 
TTGTTCAGCCACTCTGGCCTT -3’; rMMP2, 5’- 
GCACCGTCGCCCATCATCAAGT -3’ DS 5’- 25 
TTGCGGGGAAAGAAGTTGTAGT -3’; rTIMP1, US 5’- 
GACCACCTTATACCAGCGTT -3’ DS 5’-
GTCACTCTCCAGTTTGCAAG -3’;  rVimentin, US 5'- 
CAGGCCACCTCGTCCTTCGAAG -3' DS 5'- 
TGTGCCGGAGCCACCGAACAT -3'; rα-SMA, US 5'-30 
TGCCATGTATGTGGCTATTCA -3' DS 5'-
ACCAGTTGTACGTCCAGAAGC -3'. Relative expression was 
calculated based on the ΔΔCt method with gene expression 
normalised to 18S rRNA expression. 
 35 
Hydroxyproline assay 
Hydroxyproline assays were carried out using the Quickzyme 
hydroxyproline assay kit (2B Scientific, Upper Heyford, UK). 
Samples were prepared by incubating liver samples in 6M HCl 
(10mg wet weight/100ul HCl) overnight at 110°C. Following 40 
acid hydrolysis, the samples were centrifuged at 13,000rpm for 
15 minutes in a desktop centrifuge and the supernatant retained 
for the assay. 
 
Statistics 45 
Two-tailed Student’s T-tests were used to test for statistical 
significance between groups. Significance was achieved where p 
< 0.05. 
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Table 1:  Total body weight changes in rats treated with MP 
or subjected to BDL. 
 
Group %age body weight change over 2 
weeks (BDL) or 3 weeks (MP) 
Vehicle 112.4 ± 3.42 
MP 102.7 ± 2.97* 
Sham 113.2 ± 11.9 
BDL 102.2 ± 3.73* 
 
Values are mean and SD, *significantly different compared to 5 
respective controls at p <0.05. For vehicle, n=3; for MP and 
sham, n=5; for BDL, n=8. 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  9 
Table 2.  Whole liver changes in gene expression after MP treatment or 14 day BDL as measured by qPCR. 
 
         
GROUP mRNA transcript (fold control levels)  
 α-SMA COL1A1 MMP-2 TGF-β1 TGF-β2 TIMP-1 Vimentin  
        
Control 1 ± 0.24 1 ± 0.24 1 ± 0.89 1 ± 0.23 1 ± 0.47 1 ± 0.85 1 ± 0.33  
3wk MP 2.19 ± 0.47* 3.26 ± 2.1* 1.87 ± 1.22 2.82 ± 0.56* 2.05 ± 1.79 3.46 ± 2.34* 2.18 ± 1.21*  
6wk MP 4.84 ± 6.63* 4.03 ± 6.43* 4.62 ± 6.41* 3.97 ± 3.7* 3.82 ± 3.89* 7.8 ± 15.56* 3.42 ± 2.62*  
3wk MP/3 wk veh. 1.01 ± 0.26 1.39 ± 0.78 2.12 ± 1.05 1.28 ± 0.38 0.88 ± 0.3 1.14 ± 0.33 0.68 ± 0.27  
14d BDL 3.88 ± 1.83* 25.06 ± 13.74* 1.43 ± 5.09 2.71 ± 0.44* 5.78 ± 8.31* 2.83 ± 9.77 8.83 ± 2.95*  
         
Values are the mean and SD normalised to control liver. *Significance difference compared to control at p < 0.05. For control, 3wk MP 
and 3wk MP/3wk vehicle (veh), n=5; for 6wk MP, n=6 and for 14d BDL, n=8.5 
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 Figure 1: Chronic MP treatment significantly increased ALP serum activity and liver weight. A.  Serum values of ALT, AST and 
ALP in rats treated with MP for 3 weeks or subjected to BDL for 14 days. B. Liver to total body weight ratio in rats treated with MP for 
3 weeks or subject to 14 day BDL.  In all cases data are the means and SDs. *significant difference compared to respective control 5 
(p<0.05). Animal numbers - for vehicle, n=3; for MP and sham, n=5; for BDL, n=8. 
 
Figure 2: MP treatment or 14 day BDL caused periportal inflammation. A. H&E stained sections of rat liver tissue after the 
indicated treatment. Images are representative of groups and scale bar indicates 100μm. Note, control is from the vehicle control group, 
which had an identical histopathological appearance to sections from sham BDL operated rats, hence only one view is shown and 10 
referred to as control.  B. Quantified mean number of periportal inflammatory cells. Data are the mean and SD. *significant difference 
compared to the respective control group, $significant difference compared to the 3 week MP/3 week vehicle group (both p<0.05). 
Animal numbers - for control, n=3; for 3wk MP, 3wk MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for BDL n=8.  
 
Figure 3: 6 weeks chronic MP treatment or 14 day BDL caused hepatocyte and cholangiocyte proliferation. A. Rat liver sections 15 
immunostained for PCNA after the indicated treatment. Images are representative of groups and scale bar indicates 100μm. Note, control 
is from the vehicle control group, which had an identical histopathological appearance to sections from sham BDL operated rats, hence 
only one view is shown and referred to as control.  B. Quantification of periportal PCNA positive hepatocytes and cholangiocytes. Data 
are mean and SD. *significant difference compared to the respective control group (p<0.05). Animal numbers - for control, n=3; for 
sham, n=4; for 3wk MP, 3wk MP/3 wk vehicle, n=5; for 6wk MP, n=6; and for BDL n=8.  A high powered view of a portal tract 20 
identifying PCNA positive hepatocytes and cholangiocytes is given in Supplementary Figure 3.  
 
Figure 4. Chronic MP treatment or 14 day BDL caused a significant increase in periportal vimentin staining. A. Rat liver sections 
immunostained for vimentin after the indicated treatment. Images are representative of groups and scale bar indicates 100μm.  Note, 
control is from the vehicle control group, which had an identical histopathological appearance to sections from sham BDL operated rats, 25 
hence only one view is shown and referred to as control.  B. Quantified vimentin labelling of periportal regions. Values are expressed 
relative to respective controls.  Data are the mean and SD. *significant difference compared to the respective control group and 
$significant different compared to the 3 week MP/3 week vehicle group and £significant difference compared to the 3 week MP group (all 
p<0.05). Animal numbers - for control, n=3; for 3wk MP, 3wk MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for BDL n=8. 
 30 
Figure 5. Chronic MP treatment or 14 day BDLcaused significant increases in periportal myofibroblasts. A. Rat liver sections 
immunostained for α-SMA after the indicated treatment. Images are representative of groups and scale bar indicates 100μm. Note, 
control is from the vehicle control group, which had an identical histopathological appearance to sections from sham BDL operated rats, 
hence only one view is shown and referred to as control.  B. Quantification of periportal α-SMA positive cells (myofibroblasts). Data are 
the mean and SD. *significant difference compared to the respective control group, $significant different compared to the 3 week MP/3 35 
week vehicle group and £significant difference compared to the 3 week MP group (all p<0.05). Animal numbers - for control, n=3; for 
3wk MP, 3wk MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for BDL n=8.  For high powered view of staining, see 
Supplementary Figure 5 demonstrating cytoplasmic staining.  
 
Figure 6. Chronic MP treatment or 14 day BDL caused significant periportal fibrosis. A. Rat liver sections stained with sirius red 40 
after the indicated treatment. Images are representative of groups and scale bar indicates 400μm. Note, control is from the vehicle control 
group, which had an identical histopathological appearance to sections from sham BDL operated rats, hence only one view is shown and 
referred to as control.  B. Quantified sirius red staining of periportal fibrosis, values are expressed relative to respective controls.  All 
individual readings are shown, lower solid lines are the means and the dashed lines are the SD. *Significant difference compared to the 
respective control group, £significant difference compared to the 3 week MP group (all p<0.05) and †significant difference compared to 45 
the 14d BDL group. Animal numbers - for control, n=3; for 3wk MP, 3wk MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for 
BDL n=8. 
 
Figure 7: Chronic MP treatment or 14 day BDL both cause activation of a ductular reaction.  A. Rat liver sections stained with 
CK-19 after the indicated treatment. Images are representative of groups and scale bar indicates 100μm. Note, control is from the vehicle 50 
control group, which had an identical histopathological appearance to sections from sham BDL operated rats, hence only one view is 
shown and referred to as control.  B. Quantified CK19 labelling of liver sections, values are expressed relative to respective controls. 
Data are the mean and SD. *significant difference compared to the respective control group, $significant different compared to the 3 
week MP/3 week vehicle group and £significant difference compared to the 3 week MP group (all p<0.05).   Animal numbers - for 
control, n=3; for 3wk MP, 3wk MP/3 wk vehicle and sham, n=5; for 6wk MP, n=6; and for BDL n=8. 55 
 
Supplementary Figure 1:  Chronic MP liver injury is associated with neutrophil recruitment to the periportal regions of the liver 
lobule. A. Rat liver sections stained for esterase. Images are representative of groups and scale bar indicates 100μm. B. Quantified 
esterase staining of periportal regions. Bars are the mean and SD. *significant difference compared to the respective control group and 
$significant different compared to the 3 week MP/3 week vehicle group (all p<0.05). Animal numbers - for control, n=3; for 3wk MP, 60 
3wk MP/3 wk vehicle, n=5; and for 6wk MP, n=6. 
 
Supplementary Figure 2: Chronic MP treatment did not alter spleen or lung pathology. A. H&E stained sections of rat lung or 
spleen tissue in control or 6 week MP treated rats. Images are representative of groups and scale bar indicates 100μm. 
 65 
Supplementary Figure 3:  PCNA immunostain in a MP-treated rat liver section.  High magnification of liver periportal region 
immunostained for PCNA indicating typical PCNA positive hepatocytes (full arrows) and typical positive cholangiocytes (dotted 
arrows). 
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Supplementary Figure 4: Chronic MP and BDL caused significant hepatic fibrosis. A. Quantification of sirius red staining.  B. Liver 
hydroxyproline content following the indicated treatments. Data are expressed relative to respective controls and are the mean + SD. 
*Significant difference compared to the control group. Animal numbers - for control, n=3; for 3wk MP and 3wk MP/3 wk vehicle, n=5; 
6wk MP, n=6; sham, n=8 and BDL, n= 12. 
 5 
 
Supplementary Figure 5:  α-SMA immunostain in a MP-treated rat liver section.  High magnification of liver periportal region 
immunostained for α-SMA illustrating cytoplasmic staining myofibroblast cells. a, vessel region, also showing several bile ducts 
negative for α-SMA; b parenchymal region. 
10 
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